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Surgery, Erasmus Medical Center, Rotterdam, The NetherlandsBackground & Aims: Effectiveness of surveillance for hepatocel-
lular carcinoma is controversial. We here explore its effects in
‘‘real life’’ clinical practice.
Methods: Patients with hepatocellular carcinoma diagnosed in
the period 2005–2012 in five Dutch academic centers were eval-
uated. Surveillance was defined as P2 screening tests during
three preceding years and at least one radiologic imaging test
within 18 months before diagnosis.
Results: 295 (27%) of 1074 cases underwent surveillance. Median
time interval between last negative radiologic imaging and hep-
atocellular carcinoma diagnosis was 7.5 months. In the surveil-
lance group, cirrhosis (97% vs. 60%, p <0.001) and viral hepatitis
were more frequent, and non-alcoholic fatty liver disease or
absence of risk factors less frequent.
In case of surveillance, tumor size was significantly smaller
(2.7 vs. 6.0 cm), with lower alpha–fetoprotein levels (16 vs.
44 lg/L), earlier tumor stage (BCLC 0 and A combined: 61% vs.
21%) and resection/transplantation (34% vs. 25%) or radiofre-
quency ablation (23% vs. 7%) more often applied, with signifi-
cantly higher 1-, 3-, and 5-year survival rates.
Survival benefit by surveillance remained significant after
adjustment for lead-time bias based on assumed tumor doubling
time of 90 days, but not with doubling time of P120 days. In
multivariate analysis, surveillance was an independent predictorJournal of Hepatology 20
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Performance score.for mortality (for interval 69 respectively >9 months: adjusted
HRs 0.51 and 0.50, 95% confidence intervals: 0.39–0.67 and
0.37–0.69).
Conclusions: Surveillance for hepatocellular carcinoma was
associated with smaller tumor size, earlier tumor stage, with an
impact on therapeutic strategy and was an independent predictor
of survival.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Liver cancer is the sixth most common cancer in the world and
the third cause of cancer-related death [1]. Hepatocellular carci-
noma (HCC) represents more than 90% of primary liver cancers
and generally occurs in patients with underlying chronic liver
disease. In Western countries with a relatively low incidence rate
such as the Netherlands, incidence has increased in the last dec-
ade [2,3].
Currently, several international guidelines advise regular
surveillance of patients at increased HCC risk [4–6]. The goal is
to detect HCC at earlier stages enabling curative therapies with
a better outcome and decreased mortality. Nonetheless, surveil-
lance is controversial [7]. One randomized controlled trial from
China in chronic hepatitis B (HBV) patients compared surveil-
lance with combined ultrasound (US) and alpha–fetoprotein
(AFP) levels at 6-month intervals vs. no surveillance, the study
found significantly lower HCC-related mortality rates in the
surveillance group [8]. Several aspects of this study have been
criticized [7,9]. Another randomized controlled study in Chinese
HBV patients found no benefit from surveillance with AFP alone
at 6-month intervals [10]. Based on lower quality evidence, sev-
eral cohort studies suggest improved survival with surveillance
(studies summarized in references [11,12]).15 vol. 63 j 1156–1163
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Conventional US and AFP (alone or combined) are most
widely used as surveillance modalities, but their sensitivities
and specificities are far from perfect [13,14]. Moreover, the opti-
mal surveillance interval is a matter of debate [15–18].
In the present study we investigate the contribution of
surveillance in a large group of HCC patients in ‘‘real life’’ clinical





- Missing data on tumor 
characteristics (n = 37) 
- Presence of surveillance 
unknown (164) 
- HCC diagnosed during 
transplantation or autopsy 
(n = 13) 
Surveillance group 
n = 295 (27%) 
Non-surveillance group 
n = 779 (73%) 
Interval*   9 months 
n = 178 (60%) 
Interval* >9 months 
n = 117 (40%) 
Fig. 1. Flow chart of patient inclusion and details of surveillance. *Time
between date of HCC diagnosis and last negative radiologic imaging.Patients and methods
All patients with an HCC diagnosis in the period 2005–2012 in five Dutch aca-
demic centers were evaluated. Diagnosis of HCC was based on AASLD 2005 and
2011 guideline criteria [4,19]. Collected data were obtained from (electronic)
medical records. Extensive efforts were done to clarify all missing data, e.g. by
contacting patients, referring hospitals or general practitioners.
Tumor characteristics, such as number of tumor lesions, maximum diameter
of the largest tumor lesion and tumor stage according to Barcelona Clinic Liver
Cancer (BCLC) staging system, and laboratory values at time of diagnosis were
obtained for each patient. Also, data on ECOG performance status [20], clinical
symptoms such as right upper quadrant abdominal pain and weight loss
(P3 kg), presence of cirrhosis (based on clinical, laboratory, radiologic, and histo-
logic findings) and cause of underlying liver disease (including HBV and HCV,
hemochromatosis, alcohol-related liver disease (defined as P3 alcoholic drinks/-
day [21]) and non-alcoholic fatty liver disease ([NAFLD] defined as steatosis or
steatohepatitis on liver biopsy or presence of metabolic syndrome in the absence
of other risk factors for chronic liver disease such as alcohol abuse) were obtained.
Severity of liver disease was estimated by calculating the MELD score [22].
Patients were categorized as receiving surveillance (defined as at least two
screening tests (AFP and/or imaging test) during the three years before HCC diag-
nosis and at least one radiologic imaging test within 18 months before diagnosis)
or no surveillance. Additionally, time interval (i.e. time between last negative
radiological surveillance imaging and date of HCC diagnosis) for patients in the
surveillance group was determined. Patients in the surveillance groups were
divided into two subgroups based on this time interval: 69 months and
>9 months.
Patients were categorized into treatment groups based on application of sur-
gical therapy (resection or transplantation), radiofrequency ablation (RFA),
transarterial chemoembolization (TACE) or transarterial radioembolization
(TARE), sorafenib or best supportive care. Patients undergoing sequential therapy
appertaining to P2 treatment groups were included in the treatment group pre-
sumed to have most impact on outcome. In case of RFA and subsequently TACE,
with at least a 1-month interval, patients were included in the RFA group. When
combined RFA and TACE were performed within a 1-month interval, patients
were included in the TACE group.
This study was in agreement with the Declaration of Helsinki and analyses
were performed with institutional medical ethical consent, in an anonymized
database.
Statistical analysis
Continuous data are expressed as medians and ranges, and discrete variables as
absolute and relative frequencies. Mann–Whitney U or Kruskal–Wallis tests were
applied to compare continuous data in various groups. Categorical variables were
compared with Pearson’s Chi-square or Fisher’s exact tests.
Survival time was calculated from date of diagnosis to date of death or end of
follow-up (latest: end of study 1-1-2013). To deal with lead-time bias, which rep-
resents the apparently improved survival caused by the earlier diagnosis in the
course of the disease, we calculated lead-times for all patients who underwent
surveillance prior to HCC diagnosis. Lead-time was calculated by using the para-
metric model proposed by Duffy et al. [23] assuming an exponential distribution
of the HCC sojourn time. Calculated lead-time for patients in the surveillance
group was subtracted from their survival time.
Kaplan–Meier survival curves and log rank tests were used to compare sur-
vival rates between various groups. Apart from HCC surveillance, sex, age, etiol-
ogy of underlying liver disease, presence of cirrhosis, pain symptoms and
weight loss, performance score (PS), year of HCC diagnosis and MELD score were
tested as possible predictors for overall mortality by univariate Cox proportional
hazard regression analysis. Factors with a p value <0.05 in univariate analyses
were included in subsequent multivariate analyses. In a separate uni- and
multivariate analysis, BCLC stage and applied treatment were also included.
Subgroup analyses were performed in cirrhotic patients and in patients in whomJournal of Hepatology 2015surveillance is recommended according to AASLD guidelines [4]. A two-sided p
value <0.05 was considered statistically significant. Statistical analysis was per-
formed using SPSS (version 20).Results
Patient characteristics
In the period January 2005–December 2012, 1288 HCC patients
were under care in the five participating hospitals (60% of all
Dutch HCC patients in this period [3]). After exclusion of 214
patients because of missing data, 1074 (83%) were included in
this study (Fig. 1). Of all included patients, 27% (n = 295) under-
went HCC surveillance, without change during the study period.
Surveillance was performed by radiological investigations (ultra-
sound, CT, or MR imaging) alone in 17% and in combination with
AFP in 83%. Median number of surveillance tests in the three
years before HCC diagnosis was 7 (range 2–23: 4 (range 1–9)
by radiological investigations and 3 (range 0–15) by AFP). Median
time interval between last negative radiologic imaging and HCC
diagnosis was 7.5 months (range: 0.2–18 months) (69 months
in 60% of patients and >9 months in 40%).
Patient characteristics of the total group and separately for the
surveillance and non-surveillance groups are given in Table 1.
Viral hepatitis was the underlying cause for liver disease in
37%, alcohol abuse in 28%, NAFLD in 16%, hemochromatosis in
2%, and other liver diseases in 3%. Fourteen percent had no risk
factors for underlying liver disease, despite extensive investiga-
tion for potential causes. Viral hepatitis was more common in
the surveillance group (61% vs. 27%), whereas NAFLD (7% vs.
20%) or absence of cause(s) for underlying liver disease (3% vs.
18%) were more common in the non-surveillance group. Cirrhosis
was present in 97% of the surveillance and in 60% of the
non-surveillance groups (p <0.001). In the whole group, 93% of
all HCV patients exhibited a cirrhotic liver, which was the case
in 75% of HBV patients and in 24% of patients with unknown
cause for underlying liver disease. Of the patients without risk
factors for underling liver disease (n = 146), 27% had grade 62
fibrosis (based on histology), 4% grade 3 fibrosis (based onvol. 63 j 1156–1163 1157
Table 1. Patient characteristics of 1074 patients with hepatocellular carcinoma with or without previous surveillance.










Patient no. 1074 (100) 295 (27) 178 (60) 117 (40) 779 (73)
Male gender 814 (76) 229 (78) 139 (78) 90 (77) 0.814 585 (75) 0.387
Age at HCC diagnosis 
(median, range)





















Hemochromatosis 20 (2) 2 (1) 1 (<1) 1 (1) 18 (2)
Alcohol 306 (28) 71 (24) 42 (24) 29 (25) 235 (30)
NAFLD 176 (16) 22 (7) 11 (6) 11 (9) 154 (20)
Others 33 (3) 13 (4) 10 (6) 3 (3) 20 (3)
No risk factors known 146 (14) 8 (3) 5 (3) 3 (2) 138 (18)
Presence of cirrhosis 756 (70) 286 (97) 176 (99) 110 (94) 0.018 470 (60) <0.001
Results indicate numbers and, between brackets, percentages. *p value applies to differences between the two surveillance interval groups; **p value applies to differences
between the surveillance vs. non-surveillance groups; HCC, hepatocellular carcinoma; co-infection, hepatitis B+C infection. NAFLD, non-alcoholic fatty liver disease.
Research Articlehistology), 24% cirrhosis (based on histological and/or radiologi-
cal findings) and 45% no signs of cirrhosis (based on clinical, lab-
oratory and radiological findings in absence of available
histology). Furthermore, proportion of patients >75 years old
was significantly higher in the non-surveillance group than in
the surveillance group (17% vs. 8%, p <0.001).
Clinical and tumor characteristics
As indicated in Table 2, most patients had a single tumor (56%
and 50% in surveillance and non-surveillance groups, respec-
tively). Nevertheless, patients who did not receive surveillance
more often exhibited multifocal or diffuse HCC (35% vs. 20%,
respectively). In the surveillance group, tumor size was signifi-
cantly smaller (2.7 vs. 6.0 cm; p <0.001) and HCC was detected
in an earlier tumor stage (BCLC 0 and A combined: 61% vs. 21%)
than in the non-surveillance group (Table 2).
Performance scores did not differ between surveillance and
non-surveillance groups. In the non-surveillance group, right
upper quadrant abdominal pain (36% vs. 12%, p <0.001) and
weight loss (25% vs. 7%, p <0.001) at time of diagnosis were signif-
icantly more common than in the surveillance group (Table 2).
In the surveillance group, median AFP (16 lg/L vs. 44 lg/L;
p <0.001) and ALT levels (44 U/L vs. 49 U/L; p = 0.074) were lower
than in the non-surveillance group. In contrast, patients who
underwent surveillance had higher MELD scores than those in
the non-surveillance group (10 vs. 9; p <0.001) (Table 2). Tumor
size and BCLC stage increased with longer surveillance interval
(Table 2).
Treatment
In total, 28% of all patients received surgical treatment (resec-
tion/transplantation), 11% RFA, 17% TACE/TARE, 11% sorafenib
and 29% best supportive care. Details of treatment were not avail-
able in 4%. In the surveillance group, surgical treatment (34% vs.
25%) and RFA (23% vs. 7%) were more often performed than in
patients in the non-surveillance group. In total, 16% and 17% of1158 Journal of Hepatology 2015patients in the surveillance and non-surveillance groups respec-
tively, received TACE/TARE. Proportion of patients who received
sorafenib was lower in the surveillance group (3% vs. 14%).
Applied treatments did not differ between the two interval
groups (Table 2).
Survival
Data on vital status were available in 999 patients (93% of all
included patients). The median follow-up after HCC diagnosis
was 11 months (range 0.1–95) and was significantly longer in
the surveillance group (15 months vs. 10 months). In total, 58%
of all patients (n = 623) died during follow-up. Observed 1-, 3-,
and 5-year survival rates were significantly higher in the surveil-
lance group than in the non-surveillance group (68%, 47%, and 39%
vs. 55%, 29%, and 22%, respectively) (Fig. 2, log rank test p <0.001).
When evaluating the survival rates of the two time interval
groups separately, both groups had survival benefit compared to
the non-surveillance group (hazard ratio (HR) 0.64, 95% CI 0.51–
0.81 for interval 69 months and HR 0.55, 95% CI 0.42–0.73 for
interval >9 months). However, there was no significant survival
benefit in patients >75 years old in the surveillance group com-
pared to the non-surveillance group (HR 0.85, 95% CI 0.48–1.50).
Based on assumed HCC median tumor doubling times of
60 days or 90 days, survival benefit for the surveillance group
remained significant after adjustment for lead-time bias based
on the approach of Duffy et al. [23] (HR 0.74, 95% CI 0.61–0.90
and HR 0.79, 95% CI 0.65–0.95). However when HCC tumor dou-
bling time P120 days was assumed, survival benefit disappeared
(HR 0.83, 95% CI 0.69–1.01).
In multivariate analysis, surveillance was an independent
predictor for lower overall mortality (adjusted HR 0.51, 95% CI
0.39–0.67 for interval 69 months and adjusted HR 0.50, 95% CI
0.37–0.69 for interval >9 months) after adjusting for age, cause
of underlying liver disease, presence of cirrhosis, right upper
quadrant abdominal pain symptoms and weight loss, PS and
MELD score (Table 3). Nevertheless, when also adjusted for BCLC
stage and applied treatment, surveillance was no longer anvol. 63 j 1156–1163
Table 2. Clinical and tumor characteristics of 1074 patients with hepatocellular carcinoma subdivided according to presence of surveillance prior to HCC diagnosis.












Patient no. 1074 (100) 295 (27) 178 (60) 117 (40) 779 (73)
No. of lesions 0.856 <0.001
1 551 (51) 165 (56) 97 (55) 68 (58) 386 (50)
2 125 (12) 52 (18) 33 (18) 19 (16) 73 (9)
3 65 (6) 18 (6) 10 (6) 8 (7) 47 (6)
Multifocal/diffuse 333 (31) 60 (20) 38 (21) 22 (19) 273 (35)











Performance score 0.831 0.277
0 382 (36) 108 (37) 65 (37) 43 (37) 274 (35)
1 354 (33) 99 (34) 60 (34) 39 (33) 255 (33)
2 115 (11) 24 (8) 13 (7) 11 (9) 91 (11)
>2 57 (5) 12 (4) 9 (5) 3 (3) 45 (6)
Unknown 166 (15) 52 (17) 31 (17) 21 (18) 114 (15)





























BCLC stage 0.183 <0.001
0 65 (6) 43 (15) 33 (19) 10 (9) 22 (3)
A 277 (26) 136 (46) 77 (43) 59 (50) 141 (18)
B 378 (35) 61 (21) 34 (19) 27 (23) 317 (41)
C 273 (26) 37 (12) 23 (13) 14 (12) 236 (30)
D 81 (7) 18 (6) 11 (6) 7 (6) 63 (8)
ALT (U/L) 47 (4-1158) 44 (4-445) 45 (4-282) 44 (14-445) 0.651 49 (7-1158) 0.074





































RFA$ 120 (11) 66 (23) 37 (21) 29 (25) 54 (7)
TACE/TARE^ 177 (17) 48 (16) 33 (19) 15 (13) 130 (17)
Sorafenib 115 (11) 10 (3) 8 (4) 2 (2) 105 (14)
Best supportive care 313 (29) 62 (21) 29 (22) 23 (19) 250 (32)
Unknown 49 (4) 8 (3) 4 (2) 4 (3) 41 (5)
Results indicate numbers and, between brackets, percentages; Continuous variables reported as medians and ranges; $9 patients received RFA and subsequently TACE with
more than 1-month interval; ^in 28 patients combined TACE and RFA within a 1-month interval was performed as initial therapy; *p value applies to differences between
the two surveillance interval groups; **p value applies to differences between the surveillance vs. non-surveillance groups; BCLC stage, tumor stage according Barcelona
Clinic Liver Cancer staging system; ALT, alanine aminotransferase; AFP, alpha–fetoprotein; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TARE,
transarterial radioembolization.
JOURNAL OF HEPATOLOGYindependent predictor for overall mortality (Supplementary
Table 1). Analysis in the subgroup of cirrhotic patients (adjusted
HR 0.49, 95% CI 0.37–0.65 for interval 69 months and adjusted
HR 0.48, 95% CI 0.35–0.67 for interval >9 months) and in the sub-
group of patients in whom surveillance is recommended accord-
ing to AASLD guidelines (adjusted HR 0.49, 95% CI 0.37–0.65 for
interval 69 months and adjusted HR 0.49, 95% CI 0.36–0.68 for
interval >9 months) yielded similar results. On the other hand,
>62 years of age, HCV as cause of underlying liver disease, pres-Journal of Hepatology 2015ence of cirrhosis, a worse PS, right upper quadrant abdominal
pain, weight loss and a higher MELD score were independent pre-
dictors for higher overall mortality (Table 3).Discussion
This ‘‘real life’’ study showed that HCC patients who underwent
surveillance prior to diagnosis had a smaller tumor size, earliervol. 63 j 1156–1163 1159


































Log rank test p <0.001
Fig. 2. Observed survival of patients with hepatocellular carcinoma in the
surveillance group (dotted line) and non-surveillance group (solid line)
(p <0.001).
Research ArticleBCLC tumor stage and lower AFP levels, received more often sur-
gical therapy and had a better overall survival than patients with-
out surveillance. Also, in multivariate analysis, HCC surveillance
was found to be an independent predictor of better survival.
The findings are in line with previously published retrospective
cohort studies, meta-analyses and systematic reviews [11,12].
After additional adjustment for BCLC stage and applied treat-
ment, surveillance was no longer an independent predictor for
overall mortality. This interesting finding suggests that surveil-
lance allows better survival through HCC detection in earlier
BCLC stage, enabling more effective therapy. Since the two avail-
able randomized controlled trials [8,10] on HCC surveillance
yielded contradictory results [9,11], lower level of evidence from
observational studies could contribute to the advice in current
guidelines [11,13,24]. Potential limitations of observational stud-
ies are length-time bias (i.e. detection of indolent tumors by
surveillance) and/or lead-time bias (i.e. detection of tumors in
earlier stage by surveillance). Statistical techniques to adjust for
lead-time bias were performed in five earlier observational stud-
ies [25–29]: in three studies [26–28] the formula of Schwartz
et al. [30] was used, whereas the remaining studies [25,29] used
the approach of Duffy et al. [23]. In three of these, survival advan-
tage of screening disappeared with assumed tumor doubling
times of P90 days [25,26,28]. In line with these data, in the cur-
rent study survival benefit remained when tumor doubling times
of 60 or 90 days was assumed, but disappeared with doubling
times P120 days. We adjusted lead-time bias according to Duffy
et al. [23], which may be the most correct method. When we used
the formula of Schwartz et al. [30] survival benefit remained sig-
nificant with assumed tumor doubling time of 60 days, but not
with doubling times of 90 or 120 days (HR 0.82, 95% CI 0.68–
0.99, HR 0.93, 95% CI 0.77–1.12 and HR 1.03, 95% CI 0.86–1.25,
respectively).
Based on available data on HCC tumor doubling times,
approximately 40% of HCCs could have a tumor doubling time
of less than 90 days [29,31–35]. Nevertheless, this is controversial
[36] and further research is needed to evaluate HCC tumor
doubling time, to identify possible factors associated with slow-
and fast-growing tumors and to define the impact of this infor-
mation on screening strategies. Also, in a recently published
study [25] survival benefit of HCC surveillance after correction1160 Journal of Hepatology 2015for lead-time bias became evident after three years follow-up.
In the current study, median follow-up time was 11 months.
Interestingly, in most earlier observational studies, patients in
the non-surveillance group had more severe liver disease than
patients in the surveillance group [11,12]. In contrast, in the cur-
rent study, liver disease was worse in the surveillance group (cir-
rhosis in 97% vs. 60%; p <0.001 and MELD score higher: 10 vs. 9;
p <0.001) thus excluding severity of liver disease as a bias
explaining observed better survival in our surveillance group. A
potential explanation for our relatively low prevalence of cirrho-
sis in the non-surveillance group could be the relatively large
contribution of HCC without risk factors for underlying liver dis-
ease (14% of total) in our cohort (especially in the
non-surveillance group). This could be related to the low contri-
bution of viral hepatitis to HCC in the Netherlands with low
prevalence of HBV and HCV (both estimated 0.2–0.4% of the gen-
eral population [37–39]).
In previous observational studies 60–100% of patients in the
surveillance group and 20–56% of patients in the
non-surveillance group exhibited HCC within Milan criteria
[11]. In contrast, 61% of our surveillance group and 21% of our
non-surveillance group had HCC within Milan criteria. Resection
was performed in 10% of our surveillance group vs. 20% in our
non-surveillance group (3–24% in previously published surveil-
lance groups [11]) and transplantation in 23% of our surveillance
group vs. 5% of our non-surveillance group (1–30% in previously
published surveillance groups [11]). Differences in treatment
modalities applied in the current vs. previous studies could be
due, at least in part, to the high percentage (97%) of cirrhotic
patients in our surveillance group and the relatively large contri-
bution of patients without underlying liver disease (favoring
resection) in our non-surveillance group.
In the current report, observed 1-, 3-, and 5-year survival rates
were 68%, 47% and 39% vs. 55%, 29%, and 22% in the surveillance
vs. non-surveillance group, respectively. Other studies also
reported better survival in the surveillance group than in the
non-surveillance group. For comparison, previously reported
pooled 3-year survival rate of 36 studies was 51% in surveillance
groups vs. 28% in non-surveillance groups [12]. However, there
was no significant survival benefit in our patients >75 years old
who underwent surveillance. Probably, older patients are less
likely candidates for curative surgical treatment. Therefore the
cost benefit for surveillance in elderly patients needs further
investigations.
Recall strategy and adherence to follow-up are important fac-
tors for success of a surveillance program [40,41]. A large retro-
spective cohort study in HCC patients with a prior diagnosis of
cirrhosis demonstrated that only 17% received regular and 38%
inconsistent surveillance [40]. Utilization of surveillance declined
with time. In the current study median time interval between
previous negative surveillance imaging and HCC diagnosis
(7.5 months) was significantly longer than the surveillance inter-
val of 6 months that is advised in the current guidelines [4–6],
indicating that surveillance programs can be improved. Further-
more, 62% of patients in the non-surveillance group had an indi-
cation for HCC surveillance based on AASLD guideline criteria
[4,19]. However, in the majority of these patients presence of
liver disease was unknown. In the current study, virtually all
patients received surveillance by US, with or without concomi-
tant AFP. Surveillance was associated with survival benefit in
subgroups with surveillance interval 69 months as well asvol. 63 j 1156–1163
Table 3. Relation between patient/tumor characteristics and mortality in HCC patients in the Netherlands: univariate and multivariate Cox proportional hazard
regression analyses.
Patients Univariate analysis Multivariate analysis








































































































































































































MELD score 869 (87) 1.09 1.07-1.12 <0.001 1.09 1.06-1.12
Values in parentheses are percentages; Co-infection, hepatitis B+C infection; NAFLD, non-alcoholic fatty liver disease.
JOURNAL OF HEPATOLOGYsurveillance interval >9–18 months, despite significantly larger
tumor sizes in the latter group. Potential explanations could be
that many tumors in the latter group exceeded limit of ultrasono-
graphic detection only after prolonged time periods after last
negative radiological surveillance imaging and/or relatively slow
tumor growth. Similar findings were reported in a study from
Taiwan comparing 4- and 12-month US screening intervals
[17]. We cannot exclude that strict surveillance based on the rec-
ommended interval of 6 months could lead to better outcomes,
although this is difficult to achieve in clinical practice [40,42].
In the current study, survival was not only determined by
tumor features and treatment. Older age, HCV as cause ofJournal of Hepatology 2015underlying disease and higher MELD scores were independent
predictors for higher overall mortality. One previous study also
reported a positive correlation between age and mortality [15],
but this was not confirmed in other studies [16,43]. Although
Trevisani et al. [43] suggested that prognosis is independent of
etiology of liver disease, several other studies indicated that
cause of underlying liver disease is an independent risk factor
for higher mortality in HCC patients in line with our results
[44–46].
The strength of our study is that a large cohort of Western
HCC patients was included to examine the effect of surveillance
in ‘‘real life’’ clinical practice. Also, there appears to be no biasvol. 63 j 1156–1163 1161
Research Article
from overrepresentation of cirrhosis in the group without surveil-
lance (in our study, cirrhosis prevalence was higher in the
surveillance group). However, findings of this study are inher-
ently limited by the retrospective study design. Despite correc-
tion for lead-time bias, surveillance might still preferentially
detect slowly growing indolent tumors (length-time bias). Only
patients who were diagnosed or referred to one of the five Dutch
academic centers were included. HCC patients with a very poor
prognosis could not have been referred.
In conclusion, in this ‘‘real life’’ study, HCC surveillance was
associated with a smaller tumor size, earlier BCLC tumor stage,
with impact on therapeutic strategy and was an independent pre-
dictor of increased survival.Conflicts of interest
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